New Palestine, IN, United States of America

Philip Arthur Hipskind

This inventor holds 44 USPTO granted patents and 1 published patent application, plus 4 CIPO patents and 16 EPO patents, primarily in Pharmaceutical Compounds. Top assignees: Eli Lilly and Company, Deciphera Pharmaceuticals, LLC, Audion Therapeutics. Active years: 1996-2021.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Philip Arthur Hipskind. Retrieved from https://idiyas.com/inventor/philip-arthur-hipskind

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 44 (Patent Applications = 1)

% Patents Active = 54.5

CIPO Patents = 4

EPO Patents = 16 (Patent Applications = 9)

Average Co-Inventor Count = 4.3

ph-index = 13

Forward Citations = 436(Granted Patents)

Location History:

New Palastine, IN (US) (2012 - 2015)
Indianapolis, IN (US) (2015 - 2016)
New Palestine, IN (US) (1996 - 2021)

Company Filing History:

43 out of 4,514

Eli Lilly and Company

patents

2 out of 99

Deciphera Pharmaceuticals, LLC

where one patent can have more than one assignee

Years Active: 1996-2021

Loading Chart...

Areas of Expertise:

Antibody Drug Conjugates

Notch Pathway Inhibitors

RAF Inhibitors

Histamine H3 Receptor

Glucagon Receptor Antagonists

Hedgehog Pathway Antagonists

Tachykinin Receptor Antagonists

Antineoplastic Agents

Melanin Concentrating Hormone

Neuropeptide Y Receptor

44 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11167039 - MET antibody drug conjugates (2021-11-09),

2. 10450317 - Notch pathway signaling inhibitor compounds (2019-10-22),

3. 9334267 - RAF inhibitor compounds (2016-05-10),

4. 9187474 - Raf inhibitor compounds (2015-11-17),

5. 9000023 - Disubstituted phthalazine hedgehog pathway antagonists (2015-04-07),

6. 8691856 - Glucagon receptor antagonists, preparation and therapeutic uses (2014-04-08),

7. 8569286 - Notch pathway signaling inhibitor compound (2013-10-29),

8. 8507490 - Tetrasubstituted pyridazine hedgehog pathway antagonists (2013-08-13),

9. 8445493 - Tetrasubstituted pyridazines hedgehog pathway antagonists (2013-05-21),

10. 8404687 - Disubstituted phthalazine hedgehog pathway antagonists (2013-03-26),

11. 8273742 - Disubstituted phthalazine hedgehog pathway antagonists (2012-09-25),

12. 8178528 - Histamine H3 receptor agents, preparation and therapeutic uses (2012-05-15),

13. 8076374 - Glucagon receptor antagonists, preparation and therapeutic uses (2011-12-13),

14. 8030304 - Thiazole pyrazolopyrimidines CRF1 receptor antagonists (2011-10-04),

15. 8008301 - Histamine H3 receptor agents, preparation and therapeutic uses (2011-08-30),

Title: The Inventor Profile: Philip Arthur Hipskind

Introduction

Philip Arthur Hipskind, a prolific inventor hailing from New Palestine, IN, has made significant contributions to the field of medicine with his groundbreaking patents.

Latest Patents

Hipskind's latest patents showcase his innovative spirit. The MET antibody drug conjugates he developed target and eliminate MET expressing tumor cells, offering a promising treatment for cancers. Additionally, his Notch pathway signaling inhibitor compounds have shown potential in treating various cancers and sensorineural hearing loss.

Career Highlights

With an impressive 44 patents to his name, Philip Arthur Hipskind has left a lasting impact on the pharmaceutical industry. Throughout his career, he has worked with reputable companies such as Eli Lilly and Company and Deciphera Pharmaceuticals, LLC, further solidifying his expertise in the field.

Collaborations

Hipskind has had the privilege of collaborating with esteemed professionals in the industry, including Karen Lynn Lobb and James Arthur Nixon. These collaborations have not only enriched his work but have also paved the way for innovative solutions in cancer treatment and hearing loss therapies.

Conclusion

In conclusion, Philip Arthur Hipskind's inventive mind and dedication to advancing medical science have positioned him as a pioneer in the field of pharmaceuticals. His patents continue to inspire new developments and offer hope for improved treatments in the future.

Profile summary based on public USPTO records.